Table 6.

Adjusted RRs of HER2+ and HER2 breast cancer in relation to hormone levels in postmenopausal women of the ORDET cohort

HER2+
HER2
Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)
Total testosterone (median nmol/L)
    1 (0.56)4/2311.0032/2311.00
    2 (0.87)7/2002.02 (0.58-7.04)36/2001.32 (0.79-2.21)
    3 (1.25)12/1933.49 (1.09-11.2)58/1932.24 (1.39-3.60)
    P for trend0.0300.001
    Continuous1.93 (1.26-2.95)1.45 (1.18-1.79)
    P heterogeneity§0.53
Free testosterone (median pmol/L)
    1 (0.80)7/2081.0033/2081.00
    2 (1.67)7/2080.98 (0.34-2.85)37/2081.13 (0.68-1.88)
    3 (3.28)9/2081.14 (0.40-3.20)56/2081.70 (1.06-2.73)
    P for trend0.7850.018
    Continuous1.35 (0.87-2.12)1.27 (1.04-1.55)
    P heterogeneity§0.46
Estradiol (median pmol/L)
    1 (10.1)12/2081.0034/2081.00
    2 (19.3)5/2080.43 (0.15-1.26)41/2081.21 (0.74-1.99)
    3 (32.5)6/2080.43 (0.15-1.24)51/2081.54 (0.95-2.48)
    P for trend0.0950.087
    Continuous0.86 (0.61-1.21)1.15 (0.93-1.43)
    P heterogeneity§0.027
SHBG (median nmol/L)
    1 (54.9)7/2081.0042/2081.00
    2 (91.6)8/2090.95 (0.32-2.77)48/2091.11 (0.70-1.76)
    3 (141.0)8/2071.18 (0.42-3.32)36/2070.86 (0.53-1.40)
    P for trend0.7360.514
    Continuous1.30 (0.82-2.07)0.82 (0.69-0.99)
    P heterogeneity§0.52
  • * Adjusted for age, age at first birth, and family history of breast cancer.

  • P value for trend from model with the median of tertiles entered as continuous variable.

  • Log transformed.

  • § Wald test for heterogeneity.